Half-year report on Innate Pharma's liquidity contract with Natixis Securities
Innate Pharma announces today its tentative financial calendar for 2011
Initiation of a Phase II clinical trial with anti-KIR monoclonal antibody IPH2101 in smoldering myeloma patients
Innate Pharma announces today that it will participate to the “Life Science Day”
Innate Pharma announces its turnover for the first nine months of 2010 and updates on its cash situation
Innate Pharma SA announces today its financial results for the first half of 2010.
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
Final data on response rate for the Phase II trial with IPH 1101 in Follicular Lymphoma reported at the EHA meeting
Innate Pharma announces its participation to major upcoming medical meetings
Innate Pharma announces the outcome of its annual general meeting, as well as changes in the composition of its management and governance bodies
